Sensex hits 82,000, Nifty 25,000 for 1st time as US rate cut nears
Business News

Sensex hits 82,000, Nifty 25,000 for 1st time as US rate cut nears

Business new tamfitronics MUMBAI: A strong US market close the previous night backed by dovish comments by the Fed chief lifted sentiment on Dalal Street on Thursday which saw the sensex break above the 82,000 mark for the first time and the Nifty above the 25,000 milestone. The indices, however, closed lower than their respective all-time highs as profit taking at higher levels had set in due to the rising geopolitical tensions in West Asia, market players said.The day's session started on a high note with the sensex rallying to an intraday high at 82,129 points while Nifty recorded its all-time high at 25,078 points.At close, the sensex was at 81,868 points, up 126 points (0.2%) while Nifty was at 25,011 points, up 60 points (0.2%).Outside of the leading indices, there was strong...
Continue reading
Petrol, diesel sales rise in July, power demand subdued
Business News

Petrol, diesel sales rise in July, power demand subdued

Business new tamfitronics TNN / Updated: Aug 2, 2024, 06:27 ISTAAText SizeSmallMediumLarge Monsoon showers failed to cool India's appetite for petrol and diesel but subdued power consumption in July, govt data showed on Thursday. Diesel sales growth turned positive, registering a growth of 3.4% from the year-ago period, reversing the trend for last several months, while petrol demand saw a spike of 9.5% annually. Power consumption rose by a meagre 3.5% to 145.4 BUs (billion units) during the month from 140.4 BUs a year ago as widespread rains brought down temperatures.This is in contrast to 8-9% growth seen in last few months. End of ArticleFOLLOW US ON SOCIAL MEDIABusiness new tamfitronics Visual Stories Hot PicksTOP TRENDING
Continue reading
Amity Global Institute Achieves 4-Year EduTrust Certification Renewal, Business News
Business News

Amity Global Institute Achieves 4-Year EduTrust Certification Renewal, Business News

Business new tamfitronics SINGAPORE - Media OutReach Newswire - 29 July 2024 - Amity Global Institute is proud to announce the successful renewal of its 4-year EduTrust Certification for the third consecutive term, awarded by the Committee for Private Education (CPE), part of SkillsFuture Singapore (SSG). This prestigious certification underscores our unwavering commitment to excellence in education and institutional management.The EduTrust Certification is a quality assurance scheme awarded to Private Education Institutions (PEIs) that demonstrate exemplary performance in managing their institutions and providing high-quality education and student welfare. The certification process evaluates institutions across seven key criteria: management commitment and responsibilities, corporate governance, student protection and support services, academic processes and student assessment, achievement of student and graduate outcomes, quality assurance, and continual improvement.In their assessment, the CPE commended Amity Global Institute for...
Continue reading
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia, Business News
Business News

Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia, Business News

Business new tamfitronics --Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- -- Obicetrapib lowered LDL-C by 36.3% at week 12 and by 41.5% at week 52, compared to placebo -- -- Obicetrapib was well-tolerated; safety results comparable to placebo-- FLORENCE, Italy, July 29, 2024 /PRNewswire/ -- Menarini Group today announces positive topline data from the Phase 3 BROOKLYN clinical trial (NCT05425745) sponsored by NewAmsterdam Pharma Company N.V. ("NewAmsterdam"), a biopharmaceutical company which granted the Menarini Group an exclusive license to commercialize obicetrapib...
Continue reading